 SOMERSET, N.J.--BUSINESS WIRE-- LYMSM--Legend Biotech Corporation NASDAQ: LEGN Legend Biotech, a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that the U.S. Food and Drug Administration FDA has cleared its Investigational New Drug IND application to evaluate LB1901, the companys investigational autologous chimeric antigen receptor T-cell CAR-T therapy, for the treatment 